1 nd BI-RADS 3 masses stable at 12 months were
eligible.
2 ico who had a sister with breast cancer were
eligible.
3 Any patient undergoing bronchoscopy was
eligible.
4 iabetes, or coronary artery disease were not
eligible.
5 2015, with Lenstar 900 optical biometry were
eligible.
6 with a child under the age of 4.5 years were
eligible.
7 B hemoperfusion on mortality were considered
eligible.
8 e screened for the study; 379 (81%) were not
eligible.
9 e-registration healthcare professionals were
eligible.
10 0 days to 23 weeks 6 days of gestation were
eligible.
11 but without severe valvular dysfunction were
eligible.
12 the 52 towns, of whom 27 694 were considered
eligible.
13 y old, with a sister with breast cancer were
eligible.
14 sires a routine eye screening examination is
eligible.
15 or the treatment of patients with sepsis was
eligible.
16 ge ovarian cancer who qualified for PCS were
eligible.
17 to intravenous immunoglobulin treatment were
eligible.
18 participated which represented 61% of those
eligible.
19 uring the 20-month period, 214 patients were
eligible,
182 were approached, and 32 missed.
20 to immediate vaccination (of whom 3232 were
eligible,
2151 consented, and 2119 were immediately vacc
21 ed to delayed vaccination (of whom 3096 were
eligible,
2539 consented, and 2041 were vaccinated 21 da
22 Of 278 ST patients, 179 (64%) were skin test
eligible;
43 (24%) received testing and none were allerg
23 (e.g., tracheomalacia), among the remaining
eligible 497 subjects, 51% were male, 77% white persons,
24 Eligible adults met DSM-IV-R binge-eating disorder crite
25 reviewed, 158 were identified as potentially
eligible and 18 fulfilled eligibility criteria.
26 rom August 2013 to September 2014), 260 were
eligible and 78 were enrolled (mean [SD] age, 16.5 [0.73
27 ical analysis plan included all participants
eligible and correctly enrolled.
28 cluded 33 177 patients under age 65 who were
eligible and due for CRC screening and managed by the pa
29 the most relevant end points for transplant-
eligible and elderly fit patients with MM.
30 to be interviewed, 4% refused, and 80% were
eligible and participated.
31 4, 2016, we screened 587 patients; 357 were
eligible and randomly assigned to receive placebo (n=73)
32 in the state of Wisconsin would be medically
eligible and willing to donate each year at the time of
33 that between 5925 and 31 097 people might be
eligible and willing to donate each year.
34 tic review and meta-analysis, and identified
eligible articles and candidate predictors, using PubMed
35 Eligible articles had to report on cohorts of patients w
36 luation after abstracts and the full text of
eligible articles were screened.
37 Of 126 potentially
eligible articles, 26 were included in this study.
38 yses showed that only 8.1% of foods would be
eligible based on all models (e.g., most pastas without
39 we find a steady drop in the number of grant-
eligible basic-science faculty [principal investigators
40 , and 4,240 patients were deemed potentially
eligible by participating GPs.
41 implantable cardioverter-defibrillator (ICD)-
eligible cardiomyopathy patients.
42 We enrolled
eligible cases declared to the National Reference Center
43 In all
eligible cases, the diagnosis of ECD was made using clin
44 Medical records were reviewed for 1369
eligible children (712 boys [52.0%] and 657 girls [48.0%
45 In total, 477 of 604
eligible children (79.0%) were assessed.
46 rural], and sex) in all countries to recruit
eligible children aged 3-5 years from non-ethnic minorit
47 This study included
eligible children born 2002-2006 from the Norwegian Moth
48 Eligible children were randomized to ready-made or custo
49 Consecutive
eligible children with peanut allergy in 3 centers were
50 Among 19658
eligible children, 25.8% (n = 3658) received early preve
51 eligible pregnancies and gave birth to 4,998
eligible children.
52 ildren to 20.0% (95% CI, 12.4%-30.4%) in age-
eligible children.
53 In 516 subjects (79% of
eligible cohort members) who were 13 years old, serum co
54 identified 348,462 patients with one of the
eligible conditions.
55 Eligible data on prevalence of IDU, HIV antibody, HBsAg,
56 are and Medicaid Services definitions of an "
eligible death" for donation excludes patients >70 years
57 Wastewater transport from wells
eligible for 2011 impact fee disbursement calculations g
58 All surgical departments were
eligible for a financial incentive if they met a 5% cost
59 Twenty patients not
eligible for adalimumab were randomized to receive 12 we
60 on of patients receiving HPN were eventually
eligible for an intestinal transplantation.
61 A total of 15,144 admissions (10%) were
eligible for analysis once predefined exclusion criteria
62 481 women
eligible for analysis were identified retrospectively (f
63 ropean LeukemiaNet (ELN) classification were
eligible for ASCT in first remission.
64 ents with inoperable, localized HCC who were
eligible for both RFA and SBRT to evaluate the cost-effe
65 lized hepatocellular carcinoma (HCC) who are
eligible for both SBRT and RFA.
66 0% of patients with congestive heart failure
eligible for cardiac resynchronization therapy (CRT) eit
67 ary, we provide methods to identify patients
eligible for comprehensive cfDNA profiling, revealing it
68 ibroSure testing during MTX therapy and were
eligible for correlation analysis.
69 local or systemic relapse of disease may be
eligible for curative salvage surgery, but the benefit o
70 ion fraction</=48%) >/=4 days poststent were
eligible for enrollment.
71 h problems or prescription medications, were
eligible for enrollment.
72 lobectomy or bilobectomy for malignancy were
eligible for enrollment.
73 ts of all ages with a diagnosis of BCNS were
eligible for enrollment.
74 with men, a smaller proportion of women are
eligible for EVAR, a higher proportion of women are not
75 , 2013, and Feb 10, 2015, and were therefore
eligible for follow-up (1460 assigned to intervention; 1
76 $45 million toward supporting countries not
eligible for Gavi funding.
77 ositivity rate or the proportion of patients
eligible for HER2-targeted therapy.
78 014, resident women </=33 years had been age-
eligible for HPV vaccination, with 3-dose uptake across
79 Patients with CD who are
eligible for HSCT have typically been failed by most app
80 The psychiatry unit had the most patients
eligible for immediate reverse triage (72.7%; 95% CI, 59
81 Patients were
eligible for inclusion as age-matched controls if they w
82 may be at risk for cognitive impairment and
eligible for inclusion in AD prevention clinical trials.
83 ning and data extraction, and 14 trials were
eligible for inclusion in the review.
84 nts were recruited, and 24 736 patients were
eligible for inclusion in this analysis.
85 al, Stockholm, Sweden from 2011 to 2014 were
eligible for inclusion.
86 ly or confirmed diagnosis of PSP or MSA were
eligible for inclusion.
87 ipts for the 2 preceding years at least were
eligible for inclusion.
88 38 544 studies initially identified, 52 were
eligible for inclusion.
89 f follow-up after diagnosis of diabetes were
eligible for inclusion.
90 9% (n=335) of non-SHIFT-type patients became
eligible for initiation of ivabradine.
91 r dysfunction and/or symptomatic disease are
eligible for liver transplantation.
92 op quartile of proportion of patients dually
eligible for Medicare and Medicaid) and high medical ris
93 Of the 188 articles screened, 11 (5.9%) were
eligible for meta-analysis.
94 luded; providers considered 6612 (16%) to be
eligible for MMR vaccine at the time of pretravel consul
95 mized controlled trial and 30% (n = 28) were
eligible for only one of the 15.
96 Patients were
eligible for participation if they had: metastatic castr
97 ly modestly increase the number of hospitals
eligible for penalties and would substantially increase
98 o evaluate the number of hospitals that were
eligible for penalties, in that they met a volume thresh
99 ing a convenience sampling approach and were
eligible for pooling given adequate ethical approval and
100 10, 1347 patients were enrolled and 676 were
eligible for random allocation, 598 (88%) of whom were r
101 ginal studies (1327 eyes, 787 patients) were
eligible for review.
102 s (65% men; mean age, 47.4+/-9.9 years) were
eligible for speckle tracking analysis.
103 riasis (n=105), patients with hyperlipidemia
eligible for statin therapy under National Cholesterol E
104 140/90 mm Hg, 76.6% (95% CI, 75.8-77.5) were
eligible for statin treatment, but only 33.2% (95% CI, 3
105 nce of CAC, African American individuals not
eligible for statins by USPSTF guidelines had a higher A
106 ars; interquartile range [IQR], 30-46 years)
eligible for the breast cancer analysis, 5066 women (med
107 men (median age, 47 years; IQR, 40-55 years)
eligible for the contralateral breast cancer analysis, 4
108 Of these, 58 individuals were
eligible for the FABS-5+ study, could be located, and ag
109 men (median age, 38 years; IQR, 31-47 years)
eligible for the ovarian cancer analysis, and 2213 women
110 Adults (aged >/=18 years) were
eligible for the study if they had pathologically confir
111 26 054 women were
eligible for this analysis (12 807 in the intervention g
112 Of 71 patients enrolled in AURA, 53 were
eligible for this analysis.
113 idelines) or small lymphocytic lymphoma were
eligible for this phase 1b, dose-escalation trial.
114 Patients were
eligible for this randomised, double-blind, placebo-cont
115 quartile range, 4.2-10.2 ng/mL) were finally
eligible for this retrospective analysis.
116 ts at the MD Anderson Cancer Center who were
eligible for this trial but declined to participate or h
117 and assessment of early outcome in patients
eligible for transcatheter aortic valve replacement.
118 s should be investigated in patients who are
eligible for transthoracic access.
119 ART-naive children aged 0-12 years who were
eligible for treatment to receive ART within 48 h (urgen
120 patients, and identifies candidate patients
eligible for treatment.
121 te 58%); of these, 22% were in the group age-
eligible for vaccination.
122 A total of 212 of 245 (86.5%)
eligible hospitals responded.
123 Between Aug 4, and Dec 18, 2015, 2050
eligible households were enrolled in the prevalence surv
124 Eligible households were randomly assigned (1:1:1) to ei
125 A total of 14,441
eligible ICU patients.
126 Studies were considered
eligible if they examined the effects of SCFAs, prebioti
127 m 2014 to 2016, consecutive outpatients were
eligible if they had >/=1 of the following: chest/abdomi
128 Patients were
eligible if they had an ankle-brachial index (ABI) of 0.
129 Cohorts were
eligible if they had publicly available GEP data from pa
130 Patients were
eligible if they had symptomatic thrombosis (at least 5
131 Patients were
eligible if they received combination therapy for >/=48
132 Patients were
eligible if they were at least aged 18 years, had Easter
133 Women were
eligible if they were married, 15-40 years of age, 17-34
134 Studies were
eligible if they were randomised controlled trials (RCTs
135 Based on 57
eligible individual studies including 12,137 participant
136 Materials and Methods
Eligible individuals aged 58 years (n = 1984) living in
137 While statin-
eligible individuals by USPSTF guidelines did not have a
138 ciated with no significant change among DACA-
eligible individuals in terms of self-reported overall h
139 Of 82,328
eligible individuals, exactly 13,000 (15.8%) completed t
140 0, 2016, we contacted 26 518 (93%) of 28 419
eligible individuals.
141 Eligible infants were randomly assigned (1:1) to receive
142 Among
eligible infants, 87% and 86% received the third dose of
143 udy enrolled a consecutive sample of 318 AII-
eligible inpatients from a public hospital in Seattle, W
144 Although screening is covered for
eligible Medicare beneficiaries, the generalizability of
145 Among vaccine-
eligible men, the HPV vaccination coverage was 10.7% (95
146 We finally identified 4932
eligible metastatic breast cancer patients diagnosed bet
147 In total, 32
eligible non-randomized studies with 4697 patients (LLR:
148 and SNAP status [current participant, income-
eligible nonparticipant (income </=130% of the Federal P
149 A total of 1210
eligible OCT scans were analyzed, resulting in 1210 data
150 up in 2011 through 2013, and 1901 of 3280 of
eligible participants (72.1%) took part.
151 Eligible participants aged 1-18 years with newly diagnos
152 APMs have substantial advantages, with
eligible participants receiving a bonus and a higher rat
153 A total of 142
eligible participants underwent randomization at 12 Cana
154 lity occurred in 34 (4.2%) of the 812 statin-
eligible participants versus five (0.4%) of the 1,384 no
155 lity occurred in 49 (6.0%) of the 812 statin-
eligible participants versus nine (0.7%) of the 1,384 no
156 Eligible participants were aged 18-35 years in VRC19 and
157 Eligible participants were aged 6-11 years, weighed 25 k
158 Eligible participants were all women, aged 18 to 69 year
159 Eligible participants were healthy women aged 40-62 year
160 Eligible participants were HIV-uninfected men and transg
161 Eligible participants were insulin-naive patients with t
162 Eligible participants were patients with HIV who were ei
163 Eligible participants were randomized 1:1 to intravitrea
164 Eligible participants were randomly assigned to either t
165 1267
eligible participants were randomly assigned to the brie
166 Eligible participants were recruited between November 11
167 In a randomized clinical trial, 336
eligible participants who self-identified as black and 5
168 Among 6879
eligible participants, 1309 (19%) tested positive for in
169 Of 3949
eligible participants, 16% started therapy with a statin
170 lts At a median follow-up of 8.8 years among
eligible participants, five (4.5%) of 110 in the control
171 The 318 nonenrolled
eligible patients (308 patients [96.9%] of whom were fol
172 A total of 63506
eligible patients (88.6%) received CRT-D at the time of
173 In all
eligible patients (ie, trial participants plus nonenroll
174 phosphate binders, we randomly assigned 162
eligible patients (serum phosphate =6.0 to <10.0 mg/dl a
175 ine, data were collected from 305 of the 396
eligible patients and at follow up from 326 of the 392 e
176 Seventy-five percent of
eligible patients could be evaluated with the CTC0 end p
177 Eligible patients for the TH3RESA trial were men and wom
178 Eligible patients had a streptococcal PJI that was manag
179 Eligible patients had adequate end-organ function, an Ea
180 Additionally,
eligible patients had at least one of the following with
181 Eligible patients had been enrolled at one centre in the
182 Eligible patients had biopsy-proven oesophageal cancer t
183 Eligible patients had had laboratory-confirmed EVD and h
184 Eligible patients had HER2-positive advanced gastric can
185 Patients and Methods
Eligible patients had locally advanced or metastatic ccR
186 Eligible patients had measurable disease (per RECIST ver
187 Eligible patients had metastatic prostate cancer and a P
188 Eligible patients had newly diagnosed glioblastoma confi
189 riables on 5427 continuous EEG sessions from
eligible patients if they had continuous EEG for clinica
190 There were 2,508 and 2,528
eligible patients in the 2011 and 2013 cohorts, respecti
191 s and variation in CRT-D use among guideline-
eligible patients may improve patient outcomes.
192 The number of
eligible patients necessary in each randomization arm wa
193 Three out of 6
eligible patients participated in the case series.
194 Eligible patients received live zoster vaccine at invest
195 Eligible patients received oral venetoclax, starting at
196 At baseline,
eligible patients should show controlled attenuation par
197 Long-term outcome data from nonenrolled
eligible patients support the validity of the TWENTE tri
198 e remission rates that allow more transplant-
eligible patients to proceed toward consolidative high-d
199 o evaluate long-term outcomes of nonenrolled
eligible patients treated with the same DESs.
200 correlation between hospitals' proportion of
eligible patients treated within target time windows for
201 ariation in the use of CRT-D among guideline-
eligible patients undergoing ICD placement.
202 Eligible patients weighed at least 15 kg, with a confirm
203 Eligible patients were 16-60 years, and had a first CIS
204 Eligible patients were adult women (aged >/=18 years) wi
205 Eligible patients were adults with resistant hypertensio
206 Eligible patients were aged 15 years or older with a dia
207 Eligible patients were aged 16 years and older, had cont
208 Eligible patients were aged 18 years or older and had hi
209 Eligible patients were aged 18 years or older with histo
210 Eligible patients were aged 18 years or older, had a dia
211 Eligible patients were aged 18 years or older, had a pla
212 l, multicentre, single-arm, phase 1-2 trial,
eligible patients were aged 18 years or older, had histo
213 study (PACE-MDS), with long-term extension,
eligible patients were aged 18 years or older, had Inter
214 Eligible patients were aged 18-55 years, had high-risk h
215 Eligible patients were aged 18-75 years, with a diagnosi
216 Eligible patients were aged 25-75 years, had idiopathic
217 Eligible patients were aged at least 18 years, with a My
218 Eligible patients were assigned via interactive response
219 Eligible patients were drug-naive or discontinued their
220 Eligible patients were enrolled from 58 centres across 1
221 Eligible patients were offered salvage radiopharmaceutic
222 Eligible patients were randomly assigned (1:1) by an int
223 Patients who were
eligible patients were randomly assigned (1:1) via permu
224 Between May 9, 2013, and March 20, 2015, 452
eligible patients were randomly assigned to receive daco
225 Eligible patients were those 16 or older with thrombocyt
226 Eligible patients were those aged 18 years or older with
227 itors would be very large if all potentially
eligible patients were treated, which poses dilemmas for
228 Eligible patients were women with clinical T1 or T2 inva
229 me was the absolute number and proportion of
eligible patients who completed each stage of the HCV Co
230 2 year event-free survival in all registered
eligible patients who received at least 1 day of study t
231 Patients and Methods
Eligible patients with at least one prior irinotecan-con
232 Apixaban therapy for ARISTOTLE-
eligible patients with atrial fibrillation provides clin
233 Eligible patients with coronary artery disease had to ha
234 ed training by allergists to offer BLAST for
eligible patients with infectious diseases receiving non
235 Transplant-
eligible patients with relapsed/refractory HL received 2
236 nts (ie, trial participants plus nonenrolled
eligible patients), the TVF rate was only slightly highe
237 Of the
eligible patients, 1312 underwent randomization.
238 There were 1290
eligible patients, 259 treated for 1-3 days and 1031 tre
239 Of 577
eligible patients, 377 (65.3%) were enrolled and randoml
240 atients and at follow up from 326 of the 392
eligible patients, a 77% and 83% response rate respectiv
241 mong a convenience sample of 192 consecutive
eligible patients, of whom 30 declined participation.
242 Eligible patients, stratified by baseline forced vital c
243 of 2016, including 27.3% of the potentially
eligible patients.
244 priate changes to increase accessibility for
eligible patients.
245 sis and staging and provide immediate ART to
eligible patients.
246 ptable considering the poor prognosis of the
eligible patients.
247 ical prostatectomy (RP) should be offered to
eligible patients.
248 rapy boost (LDR or HDR) should be offered to
eligible patients.
249 We identified 629 study
eligible-
persons with at least one outcome.
250 Of these, 4,885 control women had 5,474
eligible pregnancies and gave birth to 4,998 eligible ch
251 Databases were searched for
eligible RCTs in 2 phases.
252 In all, 110
eligible RCTs with nonsignificant primary outcomes were
253 ur study suggests further work on converting
eligible referrals to organ donation and exploring metho
254 Of the 1473
eligible residents, 953 consented to participate in the
255 Of 3736
eligible samples, 822 were from vaccinated women accordi
256 After recruitment meetings, 120
eligible schools consented and were randomly assigned to
257 36
eligible studies (13 cohort studies comprising 3 148 259
258 We identified 41
eligible studies (24 from North America, 16 from Europe,
259 We identified 106
eligible studies comprising 29 longitudinal, 49 cross-se
260 retrieved, 24 fulfilled required criteria as
eligible studies for meta-analysis, involving a total of
261 We extracted data from
eligible studies for study characteristics, intervention
262 Five
eligible studies including 4360 patients with acute ICH
263 A total of 40
eligible studies involving 128 071 patients treated with
264 Eligible studies reported MRD status and progression-fre
265 Six
eligible studies reported on a total of 810 unique patie
266 10
eligible studies were identified.
267 Eligible studies were randomized controlled trials and o
268 Eligible studies were RCTs that compared isolated solubl
269 ducted comprehensive literature searches for
eligible studies, (3) assessed the methodological qualit
270 omes were generated by pooling patients from
eligible studies.
271 nt data from 3876 participants from 13 of 16
eligible studies.
272 Individual patient data from each
eligible study were requested from the authors.
273 A total of 35
eligible subjects underwent at least a partial surgical
274 Of 53
eligible surrogates, 32 (60%) consented to treatment all
275 Methods
Eligible survivors had curable breast or colorectal canc
276 2013 (postdisaster), and 82.1% of the 4,380
eligible survivors responded.
277 Of 1914
eligible survivors, 1503 were assessed (mean gestational
278 To identify potentially
eligible systematic reviews, we searched the Cochrane Ey
279 virus-specific T cells (VSTs) generated from
eligible,
third-party donors could provide broad antivir
280 There were 132
eligible thrombectomy patients and 132 matched controls
281 rials that are largely uninformative and not
eligible to be included in efficacy meta-analyses.
282 nts (age 1-20 years) with neuroblastoma were
eligible to be randomly assigned if they had completed a
283 Of 3288 patients
eligible to complete 3HP, 2867 (87.2%) completed treatme
284 A total of 303 children were
eligible to participate.
285 sure would result in 76 more hospitals being
eligible to receive penalties.
286 d, electronic allocation) was used to assign
eligible toddlers (in a 6:1 ratio) and infants (in a 3:1
287 g 1, 2015, and Jan 29, 2016, we enrolled 345
eligible transwomen.
288 Eligible trials had to start randomisation on or after J
289 iew and meta-analysis, we analysed data from
eligible trials that assessed the safety and efficacy of
290 We determined the publication status of
eligible trials using searches of clinicaltrials.gov, Go
291 IPD were sought from investigators with
eligible trials.
292 nguage restrictions up to Sept 18, 2017, for
eligible trials.
293 ndomised, controlled, phase 3 AZURE trial at
eligible UK sites who had stage II or III breast cancer
294 n their package (n = 747; from 1.9% of foods
eligible under Modified-PAHO to 24.2% under FSANZ-NPSC).
295 If fully implemented in
eligible US adults, intensive SBP treatment could preven
296 We performed a retrospective study of all
eligible veterans in the VA Capitol Health Care Network
297 able-turned-shockable rhythms were treatment-
eligible,
were randomized, and received their assigned d
298 population-based cohort survey study of 7303
eligible women ages 20 to 79 years with stage I and II b
299 Eligible women were randomly assigned (1:1) to receive e
300 A total of 5,006
eligible women were recruited from 29 October 2013 to 7